NCT01673529View on ClinicalTrials.gov

Investigation of Topical SB705498 on Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 17, 2012

Primary Completion Date

October 4, 2012

Study Completion Date

October 4, 2012

Conditions
Dermatitis, Atopic
Interventions
DRUG

SB705498

1%, 3% and 5% (w/w) of SB705498 will be used in part A of the study. One dose will then be selected based on criteria explained in the protocol for use in Part B of the study.

DRUG

Placebo

Placebo to match SB705498 will be used in both Part A and Part B of the study.

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01673529 - Investigation of Topical SB705498 on Healthy Volunteers | Biotech Hunter | Biotech Hunter